No Data
Luoxin pharmaceuticals group stock (002793.SZ): The non-trade transfer of the employee stock ownership plan for 2024 has been completed.
On December 2, Glonghui reported that luoxin pharmaceuticals group stock (002793.SZ) announced that on December 2, 2024, the company received the "Securities Transfer Registration Confirmation" issued by the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited, stating that the company has transferred 18,219,503 shares of its own stocks held in the repurchase special securities account to the "Luoxin Pharmaceuticals Group Co., Ltd. - 2024 Employee Stock Ownership Plan" special securities account on November 29, 2024, which accounts for 1.68% of the company's total share capital, with a transfer price of 2.03 yuan per share. This non-trade transfer.
Luoxin Pharmaceuticals Group Stock (002793.SZ): Rabeprazole Sodium Enteric-coated Tablets Obtained Pharmaceutical Registration Certificate
Galunhui November 21st | Luoxin Pharmaceuticals Group Stock (002793.SZ) announced that Shandong Yuxin Pharmaceuticals Co., Ltd., a subsidiary of Luoxin Pharmaceuticals Group Stock, recently received the Drug Registration Certificate for Rabeprazole Sodium Enteric-Coated Tablets issued by the National Medical Products Administration. Rabeprazole sodium enteric-coated tablets are a proton pump inhibitor used for gastric ulcers, duodenal ulcers, anastomotic ulcers, reflux esophagitis, and Zollinger-Ellison syndrome.
Luoxin Pharmaceuticals Group Stock (002793.SZ) shareholders De Yi Chengdu, De Yi Hengjia, and De Yi Xinhua have terminated the matter of transferring shares to Yan Jinxia.
Luoxin pharmaceuticals group stock (002793.SZ) announcement, the company's shareholder De Yi Chengdu, De Yi Hengjia, De Yi Xinhua, and Yan Jinxia...
Luoxin Pharmaceuticals Group Stock (002793.SZ): The holding subsidiary plans to sell 100% equity of its wholly-owned subsidiary, Lekang Pharmaceuticals.
On November 18, Glodon announced that luoxin pharmaceuticals group stock (002793.SZ) disclosed plans to revitalize existing assets and optimize company resource allocation. Its controlling subsidiary, shandong luoxin, intends to sell 100% of its wholly-owned subsidiary, Lekang Pharmaceutical, through public bidding at the Linyi Property Rights Trading Center. The listing price is set at 190 million yuan, based on the most recent net asset amount of Lekang Pharmaceutical, factoring in the increase in net assets after the debt-for-equity swaps in November 2024. After the completion of this transaction, the controlling subsidiary shandong luoxin will no longer hold shares in Lekang Pharmaceutical, and Lekang Pharmaceutical will not...
Luoxin Pharmaceutical: Report for the third quarter of 2024
luoxin pharmaceuticals group stock (002793.SZ) achieved a revenue of 1.881 billion yuan in the first three quarters, a year-on-year growth of 2.98%.
Gelonghui October 29th | Luoxin Pharmaceuticals Group Stock (002793.SZ) released the third quarter report for 2024, achieving a revenue of 1.881 billion yuan in the first three quarters, a year-on-year increase of 2.98%; a net loss of 0.265 billion yuan. In the third quarter alone, revenue reached 0.622 billion yuan, an 8.87% year-on-year increase; with a net loss of 0.177 billion yuan.
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s (SZSE:002793) 29% Share Price Surge Not Quite Adding Up
